PDT Partners LLC Cuts Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• PDT Partners LLC reduced its stake in Kiniksa Pharmaceuticals by 28.5% in the first quarter, leaving it with 46,407 shares valued at approximately $1,031,000.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations of $0.18, along with quarterly revenue of $156.80 million.
• Several analysts have recently updated their price targets for Kiniksa stocks, with Jefferies raising theirs from $45.00 to $54.00, while the consensus target price sits at $41.17.

PDT Partners LLC trimmed its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 28.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 46,407 shares of the company's stock after selling 18,510 shares during the quarter. PDT Partners LLC owned 0.06% of Kiniksa Pharmaceuticals International worth $1,031,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth approximately $4,663,000. Kodai Capital Management LP purchased a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $4,117,000. State of Wyoming lifted its stake in Kiniksa Pharmaceuticals International by 15.3% in the 1st quarter. State of Wyoming now owns 17,064 shares of the company's stock valued at $379,000 after buying an additional 2,258 shares in the last quarter. Trexquant Investment LP lifted its stake in Kiniksa Pharmaceuticals International by 192.5% in the 1st quarter. Trexquant Investment LP now owns 236,483 shares of the company's stock valued at $5,252,000 after buying an additional 155,641 shares in the last quarter. Finally, Ieq Capital LLC purchased a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $969,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Trading Down 0.8%

Kiniksa Pharmaceuticals International stock traded down $0.29 during trading on Tuesday, hitting $36.28. The company had a trading volume of 94,498 shares, compared to its average volume of 667,753. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $36.74. The company's 50 day simple moving average is $31.13 and its 200-day simple moving average is $26.70. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 907.23 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of research reports. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Buy" and a consensus target price of $41.17.

Insider Activity

In related news, COO Eben Tessari sold 138,614 shares of the stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the transaction, the chief operating officer directly owned 49,915 shares of the company's stock, valued at $1,657,178. This represents a 73.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Mark Ragosa sold 18,889 shares of the company's stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer owned 27,009 shares in the company, valued at $888,326.01. The trade was a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 619,649 shares of company stock valued at $20,465,432. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.